S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.28 (+0.28%)
AAPL   191.64 (-2.08%)
MSFT   368.30 (-1.58%)
META   321.10 (-3.50%)
GOOGL   132.05 (-2.18%)
AMZN   144.40 (-2.05%)
TSLA   239.88 (-1.62%)
NVDA   460.30 (-3.11%)
NIO   7.44 (+0.81%)
BABA   71.53 (-0.85%)
AMD   133.57 (+3.61%)
T   16.64 (-1.65%)
F   11.08 (+0.64%)
MU   77.64 (+3.58%)
CGC   0.80 (+0.38%)
GE   120.20 (-0.32%)
DIS   92.63 (-0.20%)
AMC   6.80 (-1.88%)
PFE   28.54 (-0.83%)
PYPL   59.26 (+0.54%)
XOM   99.45 (-0.10%)
S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.28 (+0.28%)
AAPL   191.64 (-2.08%)
MSFT   368.30 (-1.58%)
META   321.10 (-3.50%)
GOOGL   132.05 (-2.18%)
AMZN   144.40 (-2.05%)
TSLA   239.88 (-1.62%)
NVDA   460.30 (-3.11%)
NIO   7.44 (+0.81%)
BABA   71.53 (-0.85%)
AMD   133.57 (+3.61%)
T   16.64 (-1.65%)
F   11.08 (+0.64%)
MU   77.64 (+3.58%)
CGC   0.80 (+0.38%)
GE   120.20 (-0.32%)
DIS   92.63 (-0.20%)
AMC   6.80 (-1.88%)
PFE   28.54 (-0.83%)
PYPL   59.26 (+0.54%)
XOM   99.45 (-0.10%)
S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.28 (+0.28%)
AAPL   191.64 (-2.08%)
MSFT   368.30 (-1.58%)
META   321.10 (-3.50%)
GOOGL   132.05 (-2.18%)
AMZN   144.40 (-2.05%)
TSLA   239.88 (-1.62%)
NVDA   460.30 (-3.11%)
NIO   7.44 (+0.81%)
BABA   71.53 (-0.85%)
AMD   133.57 (+3.61%)
T   16.64 (-1.65%)
F   11.08 (+0.64%)
MU   77.64 (+3.58%)
CGC   0.80 (+0.38%)
GE   120.20 (-0.32%)
DIS   92.63 (-0.20%)
AMC   6.80 (-1.88%)
PFE   28.54 (-0.83%)
PYPL   59.26 (+0.54%)
XOM   99.45 (-0.10%)
S&P 500   4,603.51 (-0.02%)
DOW   36,332.72 (+0.23%)
QQQ   393.28 (+0.28%)
AAPL   191.64 (-2.08%)
MSFT   368.30 (-1.58%)
META   321.10 (-3.50%)
GOOGL   132.05 (-2.18%)
AMZN   144.40 (-2.05%)
TSLA   239.88 (-1.62%)
NVDA   460.30 (-3.11%)
NIO   7.44 (+0.81%)
BABA   71.53 (-0.85%)
AMD   133.57 (+3.61%)
T   16.64 (-1.65%)
F   11.08 (+0.64%)
MU   77.64 (+3.58%)
CGC   0.80 (+0.38%)
GE   120.20 (-0.32%)
DIS   92.63 (-0.20%)
AMC   6.80 (-1.88%)
PFE   28.54 (-0.83%)
PYPL   59.26 (+0.54%)
XOM   99.45 (-0.10%)

Immutep (IMMP) Stock Price, News & Analysis

$2.09
+0.01 (+0.48%)
(As of 11:13 AM ET)
Compare
Today's Range
$2.05
$2.10
50-Day Range
$1.76
$2.08
52-Week Range
$1.50
$3.90
Volume
14,346 shs
Average Volume
532,747 shs
Market Capitalization
$183.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Immutep MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
312.6% Upside
$8.50 Price Target
Short Interest
Healthy
0.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.42) to ($0.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

499th out of 942 stocks

Pharmaceutical Preparations Industry

217th out of 424 stocks


IMMP stock logo

About Immutep Stock (NASDAQ:IMMP)

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

IMMP Stock Price History

IMMP Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Immutep to Participate in November Investor Events
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Immutep receives ~A$1.13 million R&D Tax Incentive
Immutep to Participate in September Investor Conferences
Robert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)
IMMP - Immutep Limited
See More Headlines
Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/11/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMP
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+308.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.50 million
Book Value
$1.04 per share

Miscellaneous

Free Float
85,231,000
Market Cap
$182.89 million
Optionable
Not Optionable
Beta
2.21
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Marc Voigt (Age 50)
    CEO, MD, CFO, Chief Business Officer & Executive Director
    Comp: $367.95k
  • Ms. Deanne Miller LLB (Age 46)
    COO, General Counsel & Joint Company Secretary
    Comp: $240.62k
  • Dr. Frederic Triebel M.D. (Age 68)
    Ph.D., Chief Scientific Officer & Executive Director
    Comp: $293.73k
  • Mr. Christian Mueller BBA
    MSc., Senior Vice President of Regulatory & Strategy
  • Mr. Florian D. Vogl M.D.
    M.Sc., Ph.D., Chief Medical Officer
  • Ms. Indira Naidu
    Joint Company Secretary














IMMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Immutep stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares.
View IMMP analyst ratings
or view top-rated stocks.

What is Immutep's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for Immutep's stock. Their IMMP share price targets range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 312.6% from the stock's current price.
View analysts price targets for IMMP
or view top-rated stocks among Wall Street analysts.

How have IMMP shares performed in 2023?

Immutep's stock was trading at $1.75 at the start of the year. Since then, IMMP shares have increased by 17.7% and is now trading at $2.06.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

Who are Immutep's major shareholders?

Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Oracle Investment Management Inc. (0.59%), Meridian Wealth Management LLC (0.35%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Immutep?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IMMP) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -